These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 2829716)
21. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H; Hayakawa I; Akimoto T Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768 [TBL] [Abstract][Full Text] [Related]
22. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors. Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345 [TBL] [Abstract][Full Text] [Related]
23. N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification. Xue W; Li X; Ma G; Zhang H; Chen Y; Kirchmair J; Xia J; Wu S Eur J Med Chem; 2020 Feb; 188():112022. PubMed ID: 31901744 [TBL] [Abstract][Full Text] [Related]
32. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents. Khan T; Sankhe K; Suvarna V; Sherje A; Patel K; Dravyakar B Biomed Pharmacother; 2018 Jul; 103():923-938. PubMed ID: 29710509 [TBL] [Abstract][Full Text] [Related]
33. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2). Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Lu J; Patel S; Rickert KW; Smith RF; Soisson S; Sherer E; Joyce LA; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takano H; Shibasaki M; Yajima M; Nishimura A; Shibata T; Fukuda Y Bioorg Med Chem Lett; 2015 May; 25(9):1831-5. PubMed ID: 25851938 [TBL] [Abstract][Full Text] [Related]
34. Mode of action of the quinolone antimicrobial agents. Hooper DC; Wolfson JS Rev Infect Dis; 1988; 10 Suppl 1():S14-21. PubMed ID: 2831608 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acids. Rosen T; Chu DT; Lico IM; Fernandes PB; Marsh K; Shen L; Cepa VG; Pernet AG J Med Chem; 1988 Aug; 31(8):1598-611. PubMed ID: 2840501 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and In Silico Molecular Docking Studies on Substituted Piperic Acid Derivatives as Inhibitors of Bacterial DNA Gyrase. Chopra B; Dhingra AK; Prasad DN; Bhardwaj S; Dubey S Curr Comput Aided Drug Des; 2020; 16(3):281-294. PubMed ID: 31288729 [TBL] [Abstract][Full Text] [Related]
37. In-silico driven design and development of spirobenzimidazo-quinazolines as potential DNA gyrase inhibitors. Korrapati SB; Yedla P; Pillai GG; Mohammad F; Ch VRR; Bhamidipati P; Amanchy R; Syed R; Kamal A Biomed Pharmacother; 2021 Feb; 134():111132. PubMed ID: 33360050 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. Fan BZ; Hiasa H; Lv W; Brody S; Yang ZY; Aldrich C; Cushman M; Liang JH Eur J Med Chem; 2020 May; 193():112222. PubMed ID: 32200200 [TBL] [Abstract][Full Text] [Related]
39. Synthesis, antibacterial evaluation, and DNA gyrase inhibition profile of some new quinoline hybrids. Rizk OH; Bekhit MG; Hazzaa AAB; El-Khawass EM; Abdelwahab IA Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900086. PubMed ID: 31389630 [TBL] [Abstract][Full Text] [Related]